HIV / AIDS

Benjamin Young, MD, PhD, discusses the four partners behind the Fast-Track Cities Initiative.

Contagion® covered the 9th International AIDS Conference on HIV Science this week and much of the research presented at the conference made this week’s Top 5. Topics include: the successful use of oral Truvada in adolescents, a new long-acting two-drug injectable HIV regimen, and a closer look at humanized monoclonal antibody PRO 140 for HIV treatment. Additional Top 5 articles include coverage from the Biodefense World Summit, and lack of infant immunizations across the world.

Pedro Cahn, MD, explains the new formulation of raltegravir HD.

Kathleen Squires, MD, explains how HIV treatment has changed since the 1980s.

Nader Pourhassan, PHD, president and chief executive officer of CytoDyn, the biotechnology company that acquired PRO 140, offers insight into the antibody as treatment for HIV.

Lynne Mofenson, MD, shares an update on the health burden of mother-to-child transmission (MTCT) of HIV.

Jake Glaser discusses how generating interest for the response to HIV and AIDS has changed since the 1990s.

Due to concerns that the use of PrEP might hinder clinicians from detecting HIV in infected individuals or lead to the development of resistant strains of HIV, scientists studied how PrEP affects seroconversion after HIV is acquired.

A phase 2a clinical trial has found the dapivirine vaginal ring to be a safe and acceptable means for HIV prevention in adolescents, who showed notably high adherence when using the ring.

The NIH has released the findings of the first of 2 early-stage clinical trials on assessing the safety and effectiveness of HIV candidate vaccinations that support additional development of vaccines.

As the IAS Conference on HIV Science wraps up this week, this Public Health Watch report takes a closer look at the challenges that remain when it comes to treating HIV.

Phase 2 study finds that the use of daily oral Truvada as a means of HIV prevention is safe and acceptable.

Peter Williams, PhD, discusses the LATTE-2 trial for HIV treatment.

Magda Opsomer, MD, explains why darunavir may be more beneficial than other HIV medications.

Researchers reported at the 9th IAS Conference on HIV Science that a HIV-infected child who had been treated in infancy has maintained remission without drugs since 2008.

Ariane van der Straten, PhD, MPH, explains the different attributes of administering pre-exposure prophylaxis via a HIV biomedical implant.

A recent study finds that the majority of HIV-infected transgender women are anxious about taking ART and feminizing hormone therapy simultaneously due to hazardous drug interactions.

Leah Johnson, PhD, discusses the biomedical HIV prevention implant that is being developed by RTI International.

Kenneth Mayer, MD, explains why tenofovir alafenamide may be the future of pre-exposure prophylaxis.

WHO and IAS come together to create the first-ever global research prioritization agendas at the 9th IAS Conference on HIV Science in Paris, France.

The results of a phase 2 trial for a 2-drug regimen of long-acting cabotegravir and rilpivirine and a 3-drug regimen in patient with HIV showed comparable viral suppression rates at 96 weeks.

The World Health Organization (WHO) recently sent out a global alert warning of the growing threat of resistance to HIV drugs.

A systematic review analyzes the opportunity to provide coordinated care for HIV and noncommunicable conditions.

Women with HIV are at higher risk of having potentially cancer-causing HPV in their anal canals, raising questions about how best to screen this population.

A study published in Oxford University Press evaluates the effectiveness of several HIV diagnostic tests.

Kenneth Mayer, MD, discusses new therapies that may have a positive impact on pre-exposure prophylaxis adherence and treatment.

Benjamin Young, MD, PhD, explains the Fast-Track Cities initiative.

Although advances in HIV treatment mean many people with the condition are able to achieve viral suppression and display no outward signs of illness, kidney disease is still a fairly common occurrence in those who are infected.

The National Institutes of Health (NIH) is looking to determine whether Zika virus infection poses an additional risk in women whose pregnancies are already complicated by HIV.